8 April 2026

MedPal AI plc

("MedPal AI" or the "Company")

Technology Platform Update

Launch of the MedPal Health OS

MedPal AI (AIM: MPAL, FRA: Z1N), the AI-powered, integrated digital health company, is pleased to provide an update on its technology platform strategy and the launch of the MedPal Health Operating System ("OS").

Highlights:

•     MedPal Health OS: The Company is introducing the MedPal Health OS, a vertically integrated, closed-loop digital health platform combining wearable data, AI triage, clinician-led prescribing, and robotic dispensing - designed to make personalised, data-driven healthcare accessible to every person in the UK at ultra-low cost

•     First of its kind: The Directors believe the MedPal Health OS is the first closed-loop digital health operating system of its kind in the United Kingdom

•     100+ wearable integrations: The MedPal AI app can aggregate real-time physiological data from over 100 wearable devices and health apps to establish areal-time, data-rich health profile for each user

•     End-to-end integration: The platform connects wearable data to AI triage, clinician-led prescribing and robotic dispensing in a single continuous data loop, enabling personalised healthcare at scale

The MedPal Health OS - Closing the Bio-Feedback Loop

The MedPal Health OS integrates every stage of the patient health journey into a single, continuous data loop. The MedPal AI app aggregates real-time physiological data from over 100 wearable devices and health apps, including Apple Health, Whoop, and Garmin, to establish a real-time, data-rich health profile for each user. This "biological truth" is processed by the Company's clinician-trained AI, which generates personalised health scores and flags potential interventions. Where clinical action is indicated, the platform enables AI-assisted diagnosis supported by expert clinician review and data-backed prescribing. Medications are then fulfilled through the Company's BD Rowa VMAX robotic dispensing infrastructure at over 200 items per hour with 99.99% accuracy. Critically, once medication is delivered, the resulting physiological changes are tracked back into the wearable data layer, closing the loop and continuously refining each patient's health profile. The Company's recently announced at-home blood test kits further strengthen this bio-feedback loop, enabling users to layer clinical-grade biomarker data alongside real-time wearable inputs such as heart rate, sleep, and activity tracking for a more complete and actionable health profile.

The MedPal AI app sits at the centre of this platform. It is the front door through which millions of consumers can access the Health OS, transforming a smartphone into a personal health command centre. The app's ability to unify fragmented wearable data into a single actionable profile is a critical differentiator: it replaces the siloed model of traditional healthcare with a continuous, data-driven approach. The Board believes the app represents a significant strategic asset, both as a direct-to-consumer engagement channel and as the data engine powering the Company's clinical and pharmacy services.

The Directors believe the MedPal Health OS represents a fundamental shift from the reactive, episodic model of traditional pharmacy,where data is siloed, GP waits can exceed two weeks, and manual dispensing carries error rates of up to 2%, to a proactive, always-on system where data drives the medication and medication improves the data. The platform is designed to be accessible to every person in the UK at ultra-low cost, leveraging the Company's automated infrastructure to deliver personalised healthcare at scale.

Outlook

The Board is confident in the strategic significance of the MedPal Health OS as a platform for long-term growth. Key drivers of adoption and commercial opportunity include:

•     Health OS adoption: Roll-out of the MedPal Health OS platform to drive user engagement, clinical outcomes and long-term recurring revenue through the Company's integrated app, clinical, and pharmacy ecosystem

•     Epassi partnership: Exclusive, zero-cost access to the MedPal AI app across Epassi's network of over 11 million employees provides a substantial acquisition channel for Health OS users

•     B2B licensing: The Company plans to expand via B2B licensing to healthcare providers, businesses, and insurers, with potential use in insurance-linked wellness programmes

•     Data-driven competitive advantage: The closed-loop architecture continuously improves patient outcomes and deepens the Company's proprietary data asset, creating compounding differentiation over time

Jason Drummond, Chief Executive Officer of MedPal AI, commented:

"With the introduction of the MedPal Health OS, we are now articulating what we have been building from the outset: a closed-loop digital health platform that connects wearable data to AI triage to clinician-led prescribing to robotic dispensing and back again. Data drives the medication, and the medication improves the data. As far as we are aware, no other company in the UK is providing this end to end service.

"Our app is the key that unlocks this for millions of people. It turns a smartphone into a personal health operating system-accessible to everyone at a fraction of the cost of typical private healthcare. Combined with our pharmacy infrastructure, it gives us a platform that scales revenue while genuinely improving patient outcomes.

"The traditional pharmacy model is being disrupted, and MedPal is leading that disruption. We look forward to updating the market on continued progress."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018). The Directors of the Company are responsible for the contents of this announcement.

Enquiries:

About MedPal AI

MedPal AI is a UK-based digital health company building the MedPal Health OS - a vertically integrated, closed-loop platform spanning AI wellness, clinical services, and automated pharmacy fulfilment. Its core app aggregates data from over 100 wearable devices and health apps (including Apple Health, Fitbit, Garmin, and Whoop) into a unified health profile, offering personalised, non-clinical lifestyle guidance through its AI wellness coach and acting as the consumer front door to the Company's clinical and pharmacy services.

Through its wholly owned subsidiary MedPal Limited, the Company operates a 24/7 AI-powered automated pharmacy distribution centre, providing nationwide NHS and private prescription services. The facility leverages BD Rowa VMAX robotic dispensing technology integrated with AI triage to deliver rapid, cost-effective medication fulfilment with same-day and next-day delivery capabilities.

MedPal AI has a partnership agreement with Epassi UK Limited, which will, for a limited time, grant exclusive, zero-cost access to the MedPal AI app across Epassi's network of 11M+ employees at major firms. The Company's LEI is 984500EDP8B0A14CBA61.

Forward Looking Statements

This announcement contains forward-looking statements relating to expected or anticipated future events and anticipated results that are forward-looking in nature and, as a result, are subject to certain risks and uncertainties, such as general economic, market and business conditions, competition for qualified staff, the regulatory process and actions, technical issues, new legislation, uncertainties resulting from potential delays or changes in plans, uncertainties resulting from working in a new political jurisdiction, uncertainties regarding the results of exploration, uncertainties regarding the timing and granting of prospecting rights, uncertainties regarding the timing and granting of regulatory and other third party consents and approvals, uncertainties regarding the Company's or any third party's ability to execute and implement future plans, and the occurrence of unexpected events.